Heartseed Inc. (219A.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 2,480.00

From 52W high−35.09%

Volume814100.00

Market capJPY 55.46B

P/E (TTM)340.2x

P/S (TTM)18.3x

Div yield—

Key dataSep 18, 2026

Open

JPY 2,480.00

From 52W high

−35.09%

Volume

814100.00

Market cap

JPY 55.46B

ValuationView details →

P/E (Fwd)

396.8x

EV/EBITDA

176.3x

P/E (TTM)

340.2x

RSI (14)

73.0

MomentumView details →

1D Return

+1.65%

YTD Return

+47.56%

ValuationView details →

P/E (Fwd)

396.8x

P/E (TTM)

340.2x

EV/EBITDA

176.3x

EV/Sales

16.2x

P/S (TTM)

18.3x

P/B (TTM)

8.3x

ProfitabilityView details →

Gross Margin

100.02%

Net Margin

6.28%

EBITDA Margin

10.74%

ROE (TTM)

2.64%

ROA (TTM)

2.48%

Asset Turnover

0.39x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+246.62%

EPS CAGR 3Y

+117.07%

EBITDA YoY

—

MomentumView details →

1D Return

+1.65%

YTD Return

+47.56%

1Y Return

−27.47%

RSI (14)

73.0

vs 50D SMA

+32.44%

vs 200D SMA

+43.29%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

22.30x

Quick Ratio

22.30x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

3.01B

Net Income (TTM)

610.00M

Op. CF (TTM)

—

Next earningsNov 13, 2026 →

Latest newsMore news →

Heartseed announced clinical trial results for its iPS cell-derived cardiomyocyte product for heart failure, confirming efficacy and safety, and aims to file for approval within the year.19d ago

Heartseed applied to the Tokyo Metropolitan Government for a manufacturing and sales license for regenerative medicine products.33d ago

Similar companies

TAUNS Laboratories,Inc.197A.T ASKA Pharmaceutical Holdings Co.,Ltd.4886.T JCR Pharmaceuticals Co.,Ltd.4552.T Cuorips Inc.4894.T KYORIN Pharmaceutical Co.,Ltd.4569.T SanBio Company Limited4592.T Find similar companies →

Latest newsMore news →

Heartseed announced clinical trial results for its iPS cell-derived cardiomyocyte product for heart failure, confirming efficacy and safety, and aims to file for approval within the year.19d ago Heartseed applied to the Tokyo Metropolitan Government for a manufacturing and sales license for regenerative medicine products.33d ago